Medistim Management

Management criteria checks 4/4

Medistim's CEO is Kari Krogstad, appointed in Sep 2009, has a tenure of 13.17 years. total yearly compensation is NOK6.40M, comprised of 44.2% salary and 55.8% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth NOK16.40M. The average tenure of the management team and the board of directors is 12.3 years and 9.2 years respectively.

Key information

Kari Krogstad

Chief executive officer

NOK 6.4m

Total compensation

CEO salary percentage44.2%
CEO tenure13.2yrs
CEO ownership0.3%
Management average tenure12.3yrs
Board average tenure9.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kari Krogstad's remuneration changed compared to Medistim's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

NOK 98m

Jun 30 2022n/an/a

NOK 92m

Mar 31 2022n/an/a

NOK 93m

Dec 31 2021NOK 6mNOK 3m

NOK 91m

Sep 30 2021n/an/a

NOK 88m

Jun 30 2021n/an/a

NOK 84m

Mar 31 2021n/an/a

NOK 70m

Dec 31 2020NOK 6mNOK 3m

NOK 69m

Sep 30 2020n/an/a

NOK 71m

Jun 30 2020n/an/a

NOK 74m

Mar 31 2020n/an/a

NOK 75m

Dec 31 2019NOK 4mNOK 3m

NOK 70m

Sep 30 2019n/an/a

NOK 79m

Jun 30 2019n/an/a

NOK 73m

Mar 31 2019n/an/a

NOK 64m

Dec 31 2018NOK 4mNOK 2m

NOK 57m

Sep 30 2018n/an/a

NOK 46m

Jun 30 2018n/an/a

NOK 48m

Mar 31 2018n/an/a

NOK 45m

Dec 31 2017NOK 4mNOK 2m

NOK 48m

Sep 30 2017n/an/a

NOK 41m

Jun 30 2017n/an/a

NOK 39m

Mar 31 2017n/an/a

NOK 41m

Dec 31 2016NOK 3mNOK 2m

NOK 39m

Sep 30 2016n/an/a

NOK 45m

Jun 30 2016n/an/a

NOK 45m

Mar 31 2016n/an/a

NOK 43m

Dec 31 2015NOK 3mNOK 2m

NOK 40m

Compensation vs Market: Kari's total compensation ($USD642.44K) is below average for companies of similar size in the UK market ($USD1.02M).

Compensation vs Earnings: Kari's compensation has been consistent with company performance over the past year.


CEO

Kari Krogstad (58 yo)

13.2yrs

Tenure

NOK 6,395,468

Compensation

Ms. Kari Eian Krogstad serves as Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President. Ms. Krogst...


Leadership Team

NamePositionTenureCompensationOwnership
Kari Krogstad
CEO & President13.2yrsNOK 6.40m0.35%
NOK 16.4m
Thomas Jakobsen
Chief Financial Officerno dataNOK 2.00m0.14%
NOK 6.7m
Helge Borslid
Vice President of Operations & Manufacturingno dataNOK 1.43mno data
Hæge Johanne Wetterhus
Vice President of Marketing12.3yrsNOK 1.49m0.0036%
NOK 170.3k
Roger Morberg
Vice President of Sales12.3yrsNOK 1.71m0.070%
NOK 3.3m
Hakon Grothe
Chief Innovation Officer3.6yrsNOK 1.41m0.024%
NOK 1.1m
Ole Robsrud
CEO of Medistim Norge AS & MD of Medistim Norge ASno dataNOK 1.40m0.0073%
NOK 340.6k
Mike Farbelow
President of Medistim USA Incno dataNOK 2.86m0.011%
NOK 511.3k
Cindy Kaffai
Country Manager of Medistim Deutschland GmbHno dataNOK 1.68mno data

12.3yrs

Average Tenure

58yo

Average Age

Experienced Management: MEDIO's management team is seasoned and experienced (12.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Torben Jorgensen
Deputy Chairman2.6yrsno datano data
Oyvin Broymer
Chairman22.8yrsNOK 400.00kno data
Lars Ronn
Independent Director12.8yrsNOK 225.00k0.0019%
NOK 90.1k
Siri Furst
Independent Director9.6yrsNOK 225.00k0.011%
NOK 514.1k
Tove Raanes
Independent Director8.8yrsNOK 225.00kno data
Anthea Arff-Pettersen
Directorless than a yearno datano data

9.2yrs

Average Tenure

64yo

Average Age

Experienced Board: MEDIO's board of directors are considered experienced (9.2 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/16 13:47
End of Day Share Price 2022/08/19 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medistim ASA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Magnus GranerødBeringer Finance AB
Karl NorénDanske Bank
Simen MortensenDNB Markets